1. Diagnosticul și primul tratament al cancerului pulmonar
Pacientul Lu a fost diagnosticat cu adenocarcinom pulmonar și metastază ganglionară la 26 august 2005. O lobectomie inferioară stângă a fost efectuată pe 22 septembrie 2005. Carboplatină combinată cu taxoter a fost utilizată de 4 ori după intervenție chirurgicală. Pe 3 august 2007, din cauza efuziunii pleurale, diagnosticul a fost confirmat ca fiind recurent, iar ea a fost tratată cu Tarceva (numărul de cicluri este necunoscut). Pe 8 ianuarie 2008, la reexaminare s-a constatat progresul cancerului, apoi s-a oprit tratamentul cu Tarceva si s-a inceput tratamentul cu Libita timp de 16 cicluri. Totodată, s-au găsit metastaze vertebrale de șold și s-au efectuat 4 cicluri de Zetai.
2. Prima dată când participi la studii clinice, starea este sub control.
In July 2010, Mr. Lu reexamined a large area of brain metastasis and found dozens of small lesions in the brain. He also tested positive for the EML4-ALK fusion gene at the University of Chicago School of Medicine. The whole brain radiation therapy was then used to control the lesions, and the second phase of crizotinib drug trial was started at St. Louis University Hospital. During the treatment, the condition was stably controlled, but a re-examination in May 2012 found that the cancer had progressed slightly, and the tumoare was suspected to be resistant to crizotinib. He stopped crizotinib on July 18, 2012.
3. În al doilea studiu clinic, tumora a dispărut evident.
On August 6, 2012, Mr. Lu participated in the AP26113 drug studiu clinic at Denver Hospital. In October, the PET examination showed that the tumor disappeared and the tumoră în creier decreased and became large.
4. Descoperiți mutații genetice rare și așteptăm cu nerăbdare să participați la noi studii clinice
Reexaminarea în iulie 2014, PET-ul întregului corp a arătat: leziunile cerebrale au fost practic stabile, iar toracele a avut progrese evidente. Pe 12 mai 2014, liniile celulare cultivate suspectate de limfă anti-AP26113 (3 celule, cea mai mare 1.1 cm) au fost efectuate la Spitalul General din Massachusetts și au continuat să ia AP26113.
In August 2014, the doctor called and found that Mr. Lu’s new tumor tissue sequencing detected rare or unseen mutations. This mutation was only reported in ALK-positive children’s neuroblastom and inflammatory myofibroblastoma. Previous research reports and medical evidence have shown that crizotinib cannot cope with the resistant neuroblastoma caused by this mutation. New genetic test results indicate that Mr. Lu may need to find new drugs for treatment.
On December 8, 2014, after a doctor’s analysis and decision, Mr. Lu was approved to increase the dosage of AP26113 and changed it to 240 mg per day, so the drug replacement plan was temporarily delayed. After observing the efficacy, he decided whether to change the drug and participate in other clinical trials. The patient learned through the hospital that NIVOLUMAB monoclonal antibody imunoterapia phase 3/4 drug test is recruiting lung cancer patients on a large scale, and Mr. Lu is fully confident of the future anti-cancer.
